These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

989 related items for PubMed ID: 28457730

  • 1. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K, Wang Y, Marketkar S, Kalife ET, Steinhoff MM.
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [Abstract] [Full Text] [Related]

  • 2. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
    Xian Z, Quinones AK, Tozbikian G, Zynger DL.
    Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
    [Abstract] [Full Text] [Related]

  • 3. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H, Glasgow A, Bomeisl P, Gilmore H, Harbhajanka A.
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [Abstract] [Full Text] [Related]

  • 4. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
    VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.
    Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.
    Pekmezci M, Szpaderska A, Osipo C, Erşahin Ç.
    Int J Surg Pathol; 2013 Apr; 21(2):126-32. PubMed ID: 23204031
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S, Sarsenov D, Erdogan Z, Ordu C, Celebi F, Nur Pilanci K, Ozturk A, Selamoglu D, Alco G, Aktepe F, Eralp Y, Tuzlali S, Ozmen V.
    J BUON; 2016 Apr; 21(6):1425-1432. PubMed ID: 28039703
    [Abstract] [Full Text] [Related]

  • 11. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD, Vanner EA, Romeiser JL, Shroyer ALW, Escobar-Hoyos LF, Li J, Powers RS, Burke S, Shroyer KR.
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [Abstract] [Full Text] [Related]

  • 12. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B.
    J BUON; 2015 Apr; 20(1):28-34. PubMed ID: 25778292
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S, Himakhun W, Worasawate W, Prasert W.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1559-1565. PubMed ID: 32592349
    [Abstract] [Full Text] [Related]

  • 17. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
    Berghuis AMS, van Deurzen CHM, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ.
    Breast Cancer Res Treat; 2019 Jun 01; 175(2):451-458. PubMed ID: 30756285
    [Abstract] [Full Text] [Related]

  • 18. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.
    Breast Cancer Res; 2016 Jun 28; 18(1):68. PubMed ID: 27349894
    [Abstract] [Full Text] [Related]

  • 19. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
    van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP.
    Am J Surg Pathol; 2019 Oct 28; 43(10):1355-1360. PubMed ID: 31283631
    [Abstract] [Full Text] [Related]

  • 20. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA, Bauer KR, Brown MM, Caggiano V.
    Breast J; 2009 Oct 28; 15(6):593-602. PubMed ID: 19764994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.